Oxford Biomedica PLC Notice of Preliminary Results (2548S)
March 15 2021 - 6:03AM
UK Regulatory
TIDMOXB
RNS Number : 2548S
Oxford Biomedica PLC
15 March 2021
Notice of Preliminary Results
Oxford, UK - 15 March 2021: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, will be announcing its preliminary results for the
twelve months ended 31 December 2020 on Thursday 15 April 2021.
A virtual briefing and Q&A session for analysts will be held
at 13.00 BST / 08.00 EST on the day of results, and the
presentation and webcast details will be made available on the
Group's website at www.oxb.com . A replay webcast will be made
available shortly afterwards.
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate T: +44 (0)1865 954 161 / E: ir@oxb.com
Development & IR
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Neal T: +44 (0)20 3709 5700 /
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam
Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene
Therapy Consortium and Imperial Innovations, through which it has
long-term economic interests in other potential gene and cell
therapy products. Additionally the group has signed a 3 year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 580 people. Further
information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOREAEDSFEEFEFA
(END) Dow Jones Newswires
March 15, 2021 06:03 ET (10:03 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024